# Extensive CArdioVAscular Characterization and Follow-up of Patients Receiving Immune Checkpoint Inhibitors

> **NCT05699915** · NA · TERMINATED · sponsor: **Algemeen Ziekenhuis Maria Middelares** · enrollment: 105 (actual)

## Conditions studied

- Cancer
- Immune-related Adverse Event
- Cardiac Abnormalities, Variable
- Immune Checkpoint Inhibitor-Related Myocarditis
- Diastolic Dysfunction
- Atherosclerosis
- Cardiotoxicity

## Interventions

- **PROCEDURE:** Cardiology consultation
- **DIAGNOSTIC_TEST:** Chest Computed Tomography (CT) without contrast
- **PROCEDURE:** Non-invasive endothelial function tests
- **PROCEDURE:** Electrocardiogram
- **DIAGNOSTIC_TEST:** Extra serum sample (7.5 mL)

## Key facts

- **NCT ID:** NCT05699915
- **Lead sponsor:** Algemeen Ziekenhuis Maria Middelares
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-07
- **Primary completion:** 2024-07-12
- **Final completion:** 2024-07-12
- **Target enrollment:** 105 (ACTUAL)
- **Why stopped:** Study was stopped due to negative preliminary analysis, slow recruitment (105 patients over 2,5 years), lack of funding, need for more centers, and the changing treatment landscape (approval of ICIs in combination with other cancer treatments).
- **Last updated:** 2025-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05699915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05699915, "Extensive CArdioVAscular Characterization and Follow-up of Patients Receiving Immune Checkpoint Inhibitors". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05699915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*